Adheris Health™

Adheris Health Limited
ACN 145 327 617
Suite 287, Tenancy 111,
793 Burke Road, Camberwell, VIC 3124
investors.adherishealth.com

ASX RELEASE (ASX: AHE)

# Adheris Health Q4 FY26 Report

## Quarterly Activities Report and Appendix 4C[1]

### Key Highlights – Q4 FY26

- Revenue and profit declined on pcp, reflecting the lingering impact of the challenging pharma budget cycle in the previous period.
- Achieved cashflow break-even in Q4 FY26, as previously guided.
- Net cash at period end of $9.5 million, in line with expectations.
- Strong initial momentum with customers as they enter their next pharma budget cycle.

**Melbourne, Australia, 23 July 2026 –** Adheris Health Limited (ASX: AHE) ("Adheris Health" or "the Company") provides its quarterly activities report and Appendix 4C for the three months ended 30 June 2026 (Q4 FY26).

<u>Financial Results</u>

| AUD | Q4 FY26 | Q4 FY25 | Change |
|---|---|---|---|
| Revenue | $5.6m | $10.1m | ($4.5m) |
| Gross Profit | $2.0m | $4.3m | ($2.3m) |
| Gross Margin | 35.5% | 42.6% | (7.1 ppts) |

- Q4 FY26 operating revenue of $5.6 million was down 44.6% on pcp (Q4 FY25: $10.1 million), reflecting lower customer renewal rates during the prior pharma budgetary period, and lower bookings in 1H FY26 compared to the prior year, which impacted revenue in the current period.
- Gross profit decreased reflecting lower revenue, and gross margin decreased due to allocation of fixed platform costs against the lower revenue base. Underlying product

[1] *All references to prior periods are presented on a discontinued operations basis for comparative purposes.*

margin for Q4 FY26 was 47.6%, down 5.5 ppts from pcp, mainly as a result of a change in product mix.

- Net operating cash inflow of $0.2 million was markedly better than the prior quarter (Q3 FY26: $4.7 million outflow), influenced by the following movements:
  - Operating cash receipts were $9.3 million (Q3 FY26: $7.8 million), reflecting tighter controls over receivables management.
  - Staff costs of $3.7 million, excluding contractors and consultants (Q3 FY26: $4.1 million).
  - Administration and corporate costs of $0.9 million (Q3 FY26: $1.2 million).
  - Other operating net cash payments of $4.8 million (Q3 FY26: $7.2 million), reflecting the substantial completion of key system updates, with associated costs winding down significantly.
  - Income taxes received in Q4 of $0.2 million represent tax refunds.
  - Interest received in Q4 of $51k (Q3 FY26 of $23k).
- The FX loss on group revenue was immaterial.
- Payments to related parties of the entity and their associates were $188k. This includes fees and remuneration paid to the current CEO, the CFO and Directors.

<u>Updates on Key Short-Term Priorities</u>

We continued to advance our five key priorities over the quarter, with demonstrable progress on operational scalability, digital access to pharmacy patients, and growth in non-vaccine revenue as a percentage of the total. We make the following comments below:

| Initiative | Metric |
|---|---|
| Build a scalable operation | Staff costs, including contractors and consultants, expected to stabilise at approximately $18.2m in FY27, versus FY25 actuals of $34.0m |
| Diversify our revenue | Non-vaccine revenue as a percentage of total revenue was 83% in FY26 (54% in FY25), with increases in general medications, specialty medications and GLP-1 programs |
| Sell higher margin solutions | *Metrics to be developed and provided in future quarterly reports* |
| Expand our network | One of our largest pharmacy partners enabled our programs on their newly |

| | |
|---|---|
| | launched digital engagement platform, generating additional revenue opportunities |
| Enhance digital engagement | *Metrics to be developed and provided in future quarterly reports* |

Commenting on the results, CEO & Managing Director, John Ciccio said: *"I am proud to report that we achieved cashflow break-even in the quarter as projected. This is the result of sustained cost discipline, strengthened customer relationships, improved revenue pull-through, and out-of-cycle contract wins during a traditionally quiet sales period.*

*As we begin the new fiscal year, we've turned our attention to the next pharma budget cycle, which is now underway. Our sales team is laser focused on building a robust pipeline of opportunities that we'll work to close over the next two quarters, creating the foundation of our revenue base for calendar 2027. This is a pivotal period in our turnaround, and we're encouraged by the increased inclusion in brand planning across existing, win-back, and net new customer sets. The activity level we're seeing early in the process bodes well for the coming sales season."*

- ENDS -

*This document has been authorised for release by the Board of Adheris Health Limited.*

For more information please contact:

**Company**
Sean Slattery
Chief Financial Officer
sean.slattery@medadvisorsolutions.com
+61 417 559 360

**Investor Relations**
George Kopsiaftis
IR Department
george.kopsiaftis@irdepartment.com.au
+61 409 392 687

**About Adheris Health**

*Adheris Health (ASX: AHE) is a leader of pharmacy-driven patient engagement solutions that provide personalised patient experiences to help simplify the patient medication journey. Leveraging THRiV, a cloud-based, AI enabled platform, Adheris Health empowers the pharmacy of the future through improved pharmacy workflow and patient engagement solutions. Adheris Health works with over 25,000 pharmacies across the US with reach to over half of the population. For more information, please visit:* ***investors.adherishealth.com****.*

# Appendix 4C

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Adheris Health Ltd

| ABN | Quarter ended ("current quarter") |
|---|---|
| 17 145 327 617 | 30 June 2026 |

| Consolidated statement of cash flows | | | Current quarter $A'000 | Year to date (12 months) $A'000 |
|---|---|---|---|---|
| **1.** | **Cash flows from operating activities** | | | |
| 1.1 | Receipts from customers | | 9,317 | 33,694 |
| 1.2 | Payments for | | | |
| | (a) | research and development | - | - |
| | (b) | product manufacturing and operating costs | (4,626) | (23,286) |
| | (c) | advertising and marketing | (134) | (455) |
| | (d) | leased assets | - | (2) |
| | (e) | staff costs | (3,689) | (15,322) |
| | (f) | administration and corporate costs | (867) | (4,756) |
| 1.3 | Dividends received (see note 3) | | - | - |
| 1.4 | Interest received | | 51 | 110 |
| 1.5 | Interest and other costs of finance paid | | - | - |
| 1.6 | Income taxes received\(paid) | | 175 | 179 |
| 1.7 | Government grants and tax incentives | | - | - |
| 1.8 | Other (provide details if material) | | | - |
| **1.9** | **Net cash from / (used in) operating activities** | | **227** | **(9,838)** |

| | | | | |
|---|---|---|---|---|
| **2.** | **Cash flows from investing activities** | | | |
| 2.1 | Payments to acquire or for: | | | |
| | (a) | entities | - | - |
| | (b) | businesses | - | - |
| | (c) | property, plant and equipment | - | - |
| | (d) | investments | - | - |
| | (e) | intellectual property | - | - |
| | (f) | other non-current assets | - | - |

| Consolidated statement of cash flows | | Current quarter $A'000 | Year to date (12 months) $A'000 |
|---|---|---|---|
| 2.2 | Proceeds from disposal of: | | |
| | (a) entities | - | - |
| | (b) businesses | - | 30,218 |
| | (c) property, plant and equipment | - | - |
| | (d) investments | - | - |
| | (e) intellectual property | - | - |
| | (f) other non-current assets | - | - |
| 2.3 | Cash flows from loans to other entities | - | - |
| 2.4 | Dividends received (see note 3) | - | - |
| 2.5 | Other (provide details if material) | - | - |
| **2.6** | **Net cash from / (used in) investing activities** | **-** | **30,218** |

| | | | |
|---|---|---|---|
| **3.** | **Cash flows from financing activities** | | |
| 3.1 | Proceeds from issues of equity securities (excluding convertible debt securities) | - | 375 |
| 3.2 | Proceeds from issue of convertible debt securities | - | - |
| 3.3 | Proceeds from exercise of options | - | - |
| 3.4 | Transaction costs related to issues of equity securities or convertible debt securities | - | - |
| 3.5 | Proceeds from borrowings | - | - |
| 3.6 | Repayment of borrowings | - | (23,190) |
| 3.7 | Transaction costs related to loans and borrowings | - | - |
| 3.8 | Dividends paid | - | - |
| 3.9 | Other (provide details if material) | - | (49) |
| **3.10** | **Net cash from / (used in) financing activities** | **-** | **(22,864)** |

| | | | |
|---|---|---|---|
| **4.** | **Net increase / (decrease) in cash and cash equivalents for the period** | | |
| 4.1 | Cash and cash equivalents at beginning of period | 9,375 | 12,552 |
| 4.2 | Net cash from / (used in) operating activities (item 1.9 above) | 227 | (9,838) |
| 4.3 | Net cash from / (used in) investing activities (item 2.6 above) | - | 30,218 |

| Consolidated statement of cash flows | | Current quarter $A'000 | Year to date (12 months) $A'000 |
|---|---|---|---|
| 4.4 | Net cash from / (used in) financing activities (item 3.10 above) | - | (22,864) |
| 4.5 | Effect of movement in exchange rates on cash held | (98) | (564) |
| **4.6** | **Cash and cash equivalents at end of period** | **9,504** | **9,504** |

| **5.** | **Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts | **Current quarter $A'000** | **Previous quarter $A'000** |
|---|---|---|---|
| 5.1 | Bank balances | 9,504 | 9,375 |
| 5.2 | Call deposits | - | - |
| 5.3 | Bank overdrafts | - | - |
| 5.4 | Other (provide details) | - | - |
| **5.5** | **Cash and cash equivalents at end of quarter (should equal item 4.6 above)** | **9,504** | **9,375** |

| **6.** | **Payments to related parties of the entity and their associates** | **Current quarter $A'000** |
|---|---|---|
| 6.1 | Aggregate amount of payments to related parties and their associates included in item 1 | 188 |
| 6.2 | Aggregate amount of payments to related parties and their associates included in item 2 | - |

*Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.*

| **7.** | **Financing facilities**<br>*Note: the term "facility' includes all forms of financing arrangements available to the entity.*<br>*Add notes as necessary for an understanding of the sources of finance available to the entity.* | **Total facility amount at quarter end $A'000** | **Amount drawn at quarter end $A'000** |
|---|---|---|---|
| 7.1 | Loan facilities | - | - |
| 7.2 | Credit standby arrangements | - | - |
| 7.3 | Other (please specify) | - | - |
| 7.4 | **Total financing facilities** | - | - |

| | | |
|---|---|---|
| 7.5 | **Unused financing facilities available at quarter end** | - |

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

n\a

| **8.** | **Estimated cash available for future operating activities** | **$A'000** |
|---|---|---|
| 8.1 | Net cash from / (used in) operating activities (item 1.9) | 227 |
| 8.2 | Cash and cash equivalents at quarter end (item 4.6) | 9,504 |
| 8.3 | Unused finance facilities available at quarter end (item 7.5) | - |
| 8.4 | Total available funding (item 8.2 + item 8.3) | 9,504 |
| 8.5 | **Estimated quarters of funding available (item 8.4 divided by item 8.1)** | 41.89 |

*Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.*

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer: n\a.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer: n\a.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer: n\a.

*Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.*

## Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 23 July 2026

Authorised by: Board of Directors – Adheris Health Ltd
(Name of body or officer authorising release – see note 4)

**Notes**

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – e.g. Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.